(Q41504857)

1 October 2017

Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16. (English)

1 reference

1 October 2017

L N Petersen

1

1 reference

1 October 2017

P B Jensen

2

1 reference

1 October 2017

B S Sørensen

3

1 reference

1 October 2017

S A Engelholm

4

1 reference

1 October 2017

M Spang-Thomsen

5

1 reference

1 October 2017

language of work or name

1 reference

1 January 1994

1 reference

Investigational New Drugs

1 October 2017

1 reference

1 October 2017

12

1 reference

1 October 2017

4

1 reference

1 October 2017

289-297

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00873043

1 October 2017

0 references

cites work

Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage

1 reference

12 December 2020

Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives

1 reference

12 December 2020

In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone

1 reference

12 December 2020

Inhibition of type II topoisomerase by fostriecin

1 reference

12 December 2020

DNA topoisomerase poisons as antitumor drugs

1 reference

12 December 2020

Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.

1 reference

12 December 2020

Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs

1 reference

12 December 2020

Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.

1 reference

12 December 2020

Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I

1 reference

12 December 2020

Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines

1 reference

12 December 2020

Topoisomerase-specific drug sensitivity in relation to cell cycle progression

1 reference

12 December 2020

Characterization of three new variant type cell lines derived from small cell carcinoma of the lung.

1 reference

12 December 2020

Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial

1 reference

12 December 2020

Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II

1 reference

12 December 2020

Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons

1 reference

12 December 2020

Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.

1 reference

12 December 2020

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

1 reference

12 December 2020

Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events

1 reference

12 December 2020

Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.

1 reference

12 December 2020

Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction.

1 reference

12 December 2020

DNA double-strand breaks in mammalian cells after exposure to intercalating agents

1 reference

12 December 2020

In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin

1 reference

12 December 2020

Mammalian topoisomerase II activity is modulated by the DNA minor groove binder distamycin in simian virus 40 DNA.

1 reference

12 December 2020

Inter-experiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines.

1 reference

12 December 2020

Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00873043

1 reference

Dimensions Publication ID

1 October 2017

0 references

1 reference